The United States Patent Trial and Appeal Board has handed a win to Chinese-American synthetic biologist Feng Zhang (張鋒) and his team from the Massachusetts Institute of Technology (MIT) in a dispute over patents of the gene editing technology known as CRISPR.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Proposed MOFA budget hike seeks to counter China threat: Minister Lin
10/16/2025 12:30 PM - Science & Tech
Taiwan hospital debuts AI dialysis platform to boost efficiency, safety
10/16/2025 11:31 AM - Business
U.S. dollar down in Taipei trading
10/16/2025 10:38 AM - Business
Taiwan shares open higher
10/16/2025 09:11 AM - Society
Taiwan headline news
10/16/2025 08:47 AM